About this trial
This study compares the automated anesthesia systems for painless abortion (AAS-PA) with traditional anesthesia in painless abortions. It assesses intraoperative indicators (hypoxemia, injection pain, hypotension, hemodynamics, respiratory depression) and postoperative outcomes (nausea, dizziness, recovery time, satisfaction). The AAS-PA group uses AI-adjusted intravenous ciprofol based on real-time vital signs and sedation depth; the traditional group relies on manual anesthesia. The goal is to verify if AAS-PA safely manages sedation, meets painless standards, reduces adverse events, and improves experience, aiding optimized automated protocols.
Eligibility criteria
Qualifiers
Age between 18-45 years
ASA status Ⅰ to Ⅱ
Diagnosed with early intrauterine pregnancy
Body mass index (BMI) between 18 to 28 kg/m2
Disqualifiers
History of cardiac, hepatic, renal, or metabolic disorders (e.g., diabetes, hypertension, sleep apnea)
Known allergy to opioids or ciprofloxacin components
Cachexia
History of substance or alcohol abuse
Trial design
Treatments tested in this trial
- AI Controlled General Anesthesia
- General Anesthesia
Treatment groups
Sponsors and collaborators
Boston Intelligent Medical Research Center, Shenzhen United Scheme Technology Co., Ltd.
Lead sponsor
Fujian Provincial Hospital
Collaborator
Shishi Hospital
Collaborator
Sichuan Provincial People's Hospital
Collaborator
First Affiliated Hospital of the Chinese People's Liberation Army Naval Medical University
Collaborator
The People's Hospital of Yubei District of Chongqing city
Collaborator
Peking University Shenzhen Hospital
Collaborator
People's Hospital of Zhengzhou University
Collaborator
Jinjiang Municipal Hospital (Shanghai Sixth People's Hospital Fujian)
Collaborator